Columbia University Announces Enrollment in New Clinical Trial
Friday, March 20th, 2009Columbia University has announced enrollment in a Phase II clinical trial to determine the effectiveness of chemotherapy drug treatment program aimed at treating malignant pleural or peritoneal mesothelioma.
The trial will determine the effectiveness of a course of treatment combining the drugs oxaliplatin and gemcitabin in treating tumors in patinetes who have not received more than one previous course of chemotherapy.
Oxaliplatin and Gemcitabine inhibit the replication of cancer cells and previous studies have shown that there may be benefits in combing the drugs to help fight mesothelioma.
To be considered for the study, patients must be at least 18 years of age and have histologically confirmed malignant pleural or peritoneal mesothelioma which is not able to be treated surgically.
Please explore our website for more detailed information on Mesothelioma, including diagnosis, treatment, clinical trials, doctors and hospitals treating the disease, and your legal options.
